| | Group | Subgroup | SEN (95% CI) | SPE (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC (95% CI) |
| | Ethnicity | Asian | 0.38 (0.22, 0.58) | 1.00 (0.77, 1.00) | 176.9 (1.6, 19814.7) | 0.62 (0.45, 0.84) | 287 (3, 29034) | 0.81 (0.77, 0.84) | | European | 0.53 (0.34, 0.71) | 0.90 (0.80, 0.95) | 5.3 (2.9, 9.6) | 0.53 (0.36, 0.76) | 10 (5, 21) | 0.83 (0.79, 0.86) | | American | 0.75 (0.56, 0.87) | 0.63 (0.35, 0.84) | 2.0 (1.2, 3.5) | 0.40 (0.29, 0.35) | 5 (3, 9) | 0.76 (0.72, 0.79) |
| | Sample types | Plasma and serum | 0.55 (0.41, 0.68) | 0.90 (0.81, 0.95) | 5.5 (3.2, 9.4) | 0.50 (0.39, 0.64) | 11 (7, 18) | 0.81 (0.77, 0.84) | | Plasma | 0.50 (0.33, 0.67) | 0.88 (0.78, 0.94) | 4.3 (2.8, 6.4) | 0.57 (0.43, 0.75) | 8 (5, 11) | 0.79 (0.75, 0.82) | | Serum | 0.58 (0.39, 0.76) | 0.95 (0.77, 0.99) | 11.6 (2.8, 48.7) | 0.44 (0.29, 0.66) | 26 (7, 100) | 0.84 (0.80, 0.87) | | Urine supernatant | 0.65 (−) | 0.59 (−) | 1.59 (−) | 0.59 (−) | 2.69 (−) | — |
| | Methylation | Yes | 0.44 (0.31, 0.58) | 0.95 (0.89, 0.98) | 8.7 (4.5, 16.6) | 0.59 (0.47, 0.75) | 15 (7, 29) | 0.84 (0.80, 0.87) | | No | 0.78 (0.64, 0.88) | 0.59 (0.36, 0.78) | 1.9 (1.2, 2.9) | 0.37 (0.26, 0.53) | 5 (3, 9) | 0.76 (0.73, 0.80) |
| | Overall | | 0.56 (0.43, 0.68) | 0.89 (0.80, 0.95) | 5.1 (3.1, 8.6) | 0.49 (0.39, 0.63) | 10 (6, 17) | 0.80 (0.76, 0.83) |
|
|
SEN, sensitivity; SPE, specificity; PLR, positive likelihood ratios; PLR, positive likelihood ratios; NLR, negative likelihood ratios; DOR, diagnostic odds ratios; AUC, the area under curve.
|
